FDA grants Breakthrough Therapy Designation for Roche ’s Tecentriq in combination with Avastin as first-line treatment for advanced or metastatic hepatocellular carcinoma (HCC)
Roche today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for Tecentriq ® (atezolizumab) in combination with Avastin® (bevacizumab) as an initial (first-line) treatment for people with advanced or metastatic hepatocellular carcinoma (HCC), the most common form of liver cancer.
Source: Roche Media News - Category: Pharmaceuticals Source Type: news
More News: Avastin | Cancer | Cancer & Oncology | Carcinoma | Food and Drug Administration (FDA) | Grants | Hepatocellular Carcinoma | Liver | Liver Cancer | Pharmaceuticals | Urology & Nephrology